Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Similar articles for PubMed (Select 10704681)

1.

Alterations of P19ARF in rodent hepatoma cell lines but not in human primary liver cancer.

Laes J, Parada LA, Johansson B, Levan G, Szpirer C, Szpirer J.

Cancer Genet Cytogenet. 2000 Mar;117(2):118-24.

PMID:
10704681
2.

Cdkn2a encodes functional variation of p16INK4a but not p19ARF, which confers selection in mouse lung tumorigenesis.

Herzog CR, Noh S, Lantry LE, Guan KL, You M.

Mol Carcinog. 1999 Jun;25(2):92-8.

PMID:
10365910
3.

INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.

Tannapfel A, Busse C, Weinans L, Benicke M, Katalinic A, Geissler F, Hauss J, Wittekind C.

Oncogene. 2001 Oct 25;20(48):7104-9.

4.

Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.

Sherburn TE, Gale JM, Ley RD.

DNA Cell Biol. 1998 Nov;17(11):975-81.

PMID:
9839807
5.

p16 is a major inactivation target in hepatocellular carcinoma.

Jin M, Piao Z, Kim NG, Park C, Shin EC, Park JH, Jung HJ, Kim CG, Kim H.

Cancer. 2000 Jul 1;89(1):60-8.

PMID:
10897001
6.

High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.

Zhang YJ, Ahsan H, Chen Y, Lunn RM, Wang LY, Chen SY, Lee PH, Chen CJ, Santella RM.

Mol Carcinog. 2002 Oct;35(2):85-92.

PMID:
12325038
7.

Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.

Peng CY, Chen TC, Hung SP, Chen MF, Yeh CT, Tsai SL, Chu CM, Liaw YF.

Anticancer Res. 2002 Mar-Apr;22(2B):1265-71.

PMID:
12168936
8.

Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.

Caca K, Feisthammel J, Klee K, Tannapfel A, Witzigmann H, Wittekind C, Mössner J, Berr F.

Int J Cancer. 2002 Feb 1;97(4):481-8.

PMID:
11802210
9.

The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression.

Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M, Betticher DC.

Br J Cancer. 2001 May 18;84(10):1372-6.

10.

The rate of homozygous CDKN2A/p16 deletions in glioma cell lines and in primary tumors.

Hartmann C, Kluwe L, Lücke M, Westphal M.

Int J Oncol. 1999 Nov;15(5):975-82.

PMID:
10536182
11.

Inactivation of p16INK4 in hepatocellular carcinoma.

Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J, Hirohashi S.

Hepatology. 1996 Sep;24(3):575-9.

PMID:
8781327
12.

The human protein p19ARF is not detected in hemopoietic human cell lines that abundantly express the alternative beta transcript of the p16INK4a/MTS1 gene.

Della Valle V, Duro D, Bernard O, Larsen CJ.

Oncogene. 1997 Nov 13;15(20):2475-81. Erratum in: Oncogene 1998 Feb 26;16(8):1095.

13.

Suppression of Ras-mediated NIH3T3 transformation by p19ARF does not involve alterations of cell growth properties.

Calabrò V, Parisi T, Di Cristofano A, La Mantia G.

Oncogene. 1999 Mar 25;18(12):2157-62.

14.

Mutations, methylation and expression of CDKN2a/p16 gene in colorectal cancer and normal colonic mucosa.

Trzeciak L, Hennig E, Kolodziejski J, Nowacki M, Ostrowski J.

Cancer Lett. 2001 Feb 10;163(1):17-23.

PMID:
11163104
15.

Inactivation of both Rb and p53 pathways in mouse lung epithelial cell lines.

McDoniels-Silvers AL, Herzog CR, Tyson FL, Malkinson AM, You M.

Exp Lung Res. 2001 Apr-May;27(3):297-318.

PMID:
11293330
16.

INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.

Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A.

Virchows Arch. 2002 Aug;441(2):133-42. Epub 2002 Apr 4.

PMID:
12189502
17.

[Alternative protein p19ARF: a genuine tumor suppressor gene].

Larsen CJ.

Bull Cancer. 1998 Apr;85(4):304-6. Review. French.

PMID:
9752293
18.

Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver.

Weihrauch M, Markwarth A, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A.

Hum Pathol. 2002 Sep;33(9):884-92.

PMID:
12378512
19.

Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer.

Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, Schorderet D, Bosman FT, Chaubert P.

Lab Invest. 2001 Feb;81(2):217-29.

PMID:
11232644
20.

Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis.

Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S, Zhu J.

BMC Cancer. 2002 Nov 15;2:29. Epub 2002 Nov 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk